FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

٧	Vas	hing	iton,	D.C.	2054	.9	

neck this box if no longer subject to
ection 16. Form 4 or Form 5
ligations may continue. See
etruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* DAVIS STEPHEN						2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD									ck all appli	ionship of Reporting Pa all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	wner
(Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 10/15/2021										below) below) CEO					
(Street) SAN DII			92130 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line) K Form f Form f	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Noi	n-Deriv	ative	Sec	curiti	ies Ac	quired,	Dis	posed o	of, or E	ene	ficiall	y Owne	d			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4					es ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock				10/15	15/2021				М		5,938	3 <i>A</i>	1	(1)	55,	55,869 ⁽²⁾		D	
Common	Stock			10/18	3/2021				S ⁽³⁾		2,963	3 I)	\$17.4	1 52	,906		D	
		Т	able II -								osed of converti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, Transac Code (In			tion of		6. Date Expiration (Month/Da	n Date	:	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisal		Expiration Date	Title	or Nu of	umber					
Restricted Stock	(1)	10/15/2021			M			5,938	(4)		(4)	Commo Stock	n 5	,938	\$0.00	5,938		D	

Explanation of Responses:

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ common \ stock.$
- 2. Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program.
- 3. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- 4. The restricted stock units vest in four equal annual installments beginning 10/15/19.

Remarks:

/s/ Austin D. Kim, Attorney-in-Fact

10/19/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.